SWOG 1500 trial

Dr. Pal (US) talks about his ASCO GU21 presentation “Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study”.